PDCD1 and neoplasm: Although the anti-PD1 monotherapy was effective in reducing tumor growth after 3 weeks when compared to the control group (p < 0.0001), the combination of anti-PD1 + L-DOS47 showed the greatest efficacy and had a synergistic effect when compared to the anti-PD1 monotherapy (p = 0.03 for week 2 and p = 0.01 for week 3) (Figure 4b–d; Table 1).